Tirzepatide and Semaglutide Linked to Lower Anxiety and Depression in Obesity
A large real-world study finds GLP-1 drugs cut anxiety and depression risk vs. older weight-loss meds — but tirzepatide raises insomnia flags.
Summary
A U.S. electronic health records study followed obese adults who started tirzepatide or semaglutide for up to two years, comparing their mental health outcomes against those on older weight-loss medications like naltrexone-bupropion. Both GLP-1-based drugs were associated with substantially lower rates of newly diagnosed anxiety and depression compared to naltrexone-bupropion, regardless of whether patients had type 2 diabetes. However, among people without type 2 diabetes, tirzepatide users had modestly higher rates of anxiety disorder and insomnia compared to semaglutide users. These findings suggest meaningful neuropsychiatric differences between these popular medications and highlight the need for tailored monitoring in clinical practice.
Detailed Summary
Millions of people are now starting GLP-1 receptor agonists and dual GIP/GLP-1 agonists for obesity, yet their real-world neuropsychiatric profiles remain poorly characterized. Understanding how these drugs affect mental health is crucial for prescribing decisions and patient monitoring.
Researchers analyzed U.S. electronic health records from 2020 to 2025, identifying adults with obesity who newly initiated tirzepatide or semaglutide and matching them one-to-one with new users of naltrexone-bupropion, phentermine, or phentermine-topiramate. Participants were followed for up to 24 months for incident neuropsychiatric diagnoses. Results were stratified by the presence or absence of type 2 diabetes, with bariatric surgery patients included as a contextual comparator.
Both tirzepatide and semaglutide were associated with meaningfully lower hazards of anxiety disorder and depression compared to naltrexone-bupropion across both diabetic and non-diabetic groups. The effects were particularly pronounced for tirzepatide in people with type 2 diabetes, where hazard ratios for depression dropped to 0.49. Among people without type 2 diabetes, however, tirzepatide was associated with modestly higher hazards of anxiety disorder (HR 1.12) and insomnia (HR 1.13) relative to semaglutide — a clinically noteworthy signal.
These findings carry practical weight for clinicians counseling patients on weight-loss drug selection. The data suggest GLP-1-class drugs may confer mental health benefits over some alternatives, but the tirzepatide-versus-semaglutide differences in non-diabetic patients warrant careful monitoring, particularly for sleep and anxiety symptoms.
Important caveats apply. This is an observational study using real-world records, meaning residual confounding — including differences in baseline psychiatric burden, socioeconomic status, and prescribing patterns — cannot be ruled out. Diagnosis misclassification in electronic health records is also a known limitation. The summary is based on the abstract only, as the full text was not available.
Key Findings
- Semaglutide linked to 27–33% lower anxiety risk vs. naltrexone-bupropion in both diabetic and non-diabetic adults.
- Tirzepatide associated with 45–51% lower depression hazard vs. naltrexone-bupropion in adults with type 2 diabetes.
- In non-diabetic adults, tirzepatide users had 12% higher anxiety and 13% higher insomnia risk than semaglutide users.
- Both GLP-1 drugs outperformed naltrexone-bupropion on depression outcomes regardless of diabetes status.
- Bariatric surgery served as an additional contextual comparator to contextualize medication effects.
Methodology
Retrospective active-comparator new-user cohort study using a U.S. electronic health record network (2020–2025). Adults with obesity initiating tirzepatide or semaglutide were matched 1:1 with initiators of naltrexone-bupropion, phentermine, or phentermine-topiramate and followed for up to 24 months for incident neuropsychiatric diagnoses. Results were stratified by type 2 diabetes status.
Study Limitations
As an observational real-world study, residual confounding from unmeasured variables such as baseline psychiatric history and socioeconomic factors cannot be excluded. Electronic health record-based diagnosis misclassification is a known limitation. This summary is based on the abstract only, as the full text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: